Cabaletta Bio (CABA) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Cabaletta Bio (CABA) over the past year, gaining 82.9% versus a loss of 15.1%. Over five years, SRZN leads with a -73.5% price change compared with -83.9% for CABA. Surrozen is the larger company by market cap ($331.5 million vs $328.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | SRZN |
|---|---|---|
| Share price | $1.94 | $28.20 |
| Market cap | $328.92M | $331.45M |
| 1-day change | -1.52% | +12.15% |
| YTD return | -10.05% | +11.26% |
| 1-year return | -15.09% | +82.87% |
| 5-year return | -83.93% | -73.48% |
| EPS (TTM) | $-1.51 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $37.83 |
| 52-week low | $1.83 | $11.39 |
| Distance from 52-week high | -54.14% | -25.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +582.99% | +71.63% |
| Average volume | 4.67M | 475.02K |
| Shares outstanding | 169.55M | 11.75M |
| Employees | 154 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed CABA by 98.0 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
CABA vs SRZN FAQ
Which is bigger, Cabaletta Bio or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $331.45M compared with $328.92M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -15.09% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.